About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker MDGL · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026Resmetirom in Patients With MASH and HFpEF
NCT07830758 · MASH - Metabolic Dysfunction-Associated Steatohepatitis, He…
Resmetirom, Placebo
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Recruiting90Nov 2027Registry ↗
Oct 16, 2026Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and…
NCT07848191 · MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rezdiffra, Resmetirom
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 4Recruiting150Nov 2027Registry ↗
Sep 11, 2026Study of Resmetirom in Children and Adolescents With MASH
NCT07763015 · MASH, MASH - Metabolic Dysfunction-Associated Steatohepatit…
Resmetirom
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 2Recruiting61Jul 2029Registry ↗
Aug 26, 2026Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601 · MASH - Metabolic Dysfunction-Associated Steatohepatitis
Resmetirom, Placebo
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 2Recruiting120Aug 2028Registry ↗
Jul 8, 2026A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-com…
NCT05500222 · NASH, Cirrhosis, Liver
Resmetirom, Placebo
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 3Active, not recruiting845Dec 2026Registry ↗
Jun 4, 2026Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT03038022 · Heterozygous Familial Hypercholesterolemia
MGL-3196 (resmetirom), Placebo
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 2Completed116Jan 15, 2018Registry ↗
Jun 1, 2026A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH…
NCT03900429 · NASH - Nonalcoholic Steatohepatitis
MGL-3196, Placebo
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 3Active, not recruiting1,759Jan 2028Registry ↗
May 27, 2026A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alc…
NCT04951219 · Non-Alcoholic Fatty Liver Disease
Resmetirom
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 3Active, not recruiting810Mar 2027Registry ↗
Apr 21, 2026Rezdiffra Pregnancy and Lactation Registry
NCT07541469 · MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rezdiffra
MDGL
Madrigal Pharmaceuticals, Inc.
—Recruiting10Apr 8, 2030Registry ↗
Dec 23, 2025Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
NCT02912260 · Non-alcoholic Steatohepatitis
MGL-3196, Placebo
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 2Completed125Oct 25, 2017Registry ↗
Oct 14, 2025A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days)…
NCT06397872 · Renal Impairment
100 mg Resmetirom Tablet
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed28Sep 16, 2024Registry ↗
Oct 5, 2023Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of…
NCT04643795 · Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
MGL-3196
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed87Aug 4, 2021Registry ↗
Sep 5, 2023A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty L…
NCT04197479 · Non-Alcoholic Fatty Liver Disease
Placebo, Resmetirom
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 3Completed1,343Jan 6, 2023Registry ↗
Aug 22, 2023Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects
NCT01367873 · Drug Safety
Placebo, VIA-3196
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed72Oct 2011Registry ↗
Sep 2, 2022Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
NCT02542969 · Healthy
Simvastatin, Rosuvastatin
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed25Oct 2015Registry ↗
Dec 28, 2020Drug Interaction Study of MGL-3196 With Clopidogrel
NCT04671069 · Healthy
MGL-3196, Clopidogrel
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed20Aug 30, 2019Registry ↗
Dec 17, 2020Drug Interaction Study of MGL-3196 With Pioglitazone
NCT04671056 · Healthy
MGL-3196, Pioglitazone 15mg
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed16Dec 11, 2018Registry ↗
Sep 18, 2019Bioavailability Study of MGL-3196 Tablets Compared to Capsules
NCT03413124 · Healthy
MGL-3196 Tablet, MGL-3196 Capsule
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed16Feb 17, 2018Registry ↗
Dec 19, 2017Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
NCT03220165 · Healthy
MGL-3196
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed8Sep 3, 2017Registry ↗
Aug 30, 2016Drug Interaction Study of MGL-3196 With Atorvastatin
NCT02749578 · Healthy
Atorvastatin, MGL-3196
MDGL
Madrigal Pharmaceuticals, Inc.
Phase 1Completed14May 2016Registry ↗

20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:36 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances